Skip to content

AnaptysBio, Inc. ANAB Preferred Stock

Preferred Stock at other companies

Biogen logo
BiogenBIIB
$0
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$0
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$0
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$0
ADMA Biologics logo
ADMA BiologicsADMA
$0
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$0

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.73B+180%
Enterprise value$1.48B+176%
P/S7.4×+1.9×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AnaptysBio, Inc.'s preferred stock?
AnaptysBio, Inc. (ANAB) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.